A meta-analysis and real-world cohort study on the sex-related differences in efficacy and safety of immunotherapy for hepatocellular carcinoma
Balcar L, Scheiner B, Fulgenzi C, D'Alessio A, Pomej K, Roig M, Meyer E, Che J, Nishida N, Lee P, Wu L, Ang C, Krall A, Saeed A, Stefanini B, Cammarota A, Pressiani T, Abugabal Y, Chamseddine S, Wietharn B, Parisi A, Huang Y, Phen S, Vivaldi C, Salani F, Masi G, Bettinger D, Vogel A, von Felden J, Schulze K, Silletta M, Trauner M, Samson A, Wege H, Piscaglia F, Galle P, Stauber R, Kudo M, Singal A, Itani A, Ulahannan S, Parikh N, Cortellini A, Kaseb A, Rimassa L, Chon H, Pinato D, Pinter M
JHEP REP. 2024;6(2):100982.

Characteristics and outcomes of immunotherapy-related liver injury in patients with hepatocellular carcinoma versus other advanced solid tumours
Celsa C, Cabibbo G, Am Fulgenzi C, Scheiner B, Antonio d'Alessio , Manfredi G, Nishida N, Ang C, Marron T, Saeed A, Wietharn B, Pinter M, Cheon J, Huang Y, Lee P, Phen S, Gampa A, Pillai A, Vivaldi C, Salani F, Masi G, Roehlen N, Thimme R, Vogel A, Schönlein M, von Felden J, Schulze K, Wege H, Galle P, Kudo M, Rimassa L, Singal A, El Tomb P, Ulahannan S, Parisi A, Chon H, Hsu W, Stefanini B, Verzoni E, Giusti R, Veccia A, Catino A, Aprile G, Guglielmini P, Di Napoli M, Ermacora P, Antonuzzo L, Rossi E, Verderame F, Zustovich F, Ficorella C, Di Pietro F, Battelli N, Negrini G, Grossi F, Bordonaro R, Pipitone S, Banzi M, Ricciardi S, Laera L, Russo A, De Giorgi U, Cavanna L, Sorarù M, Montesarchio V, Bordi P, Brunetti L, Pinto C, Bersanelli M, Cammà C, Cortellini A, Pinato D
J HEPATOL. 2024;80(3):431-442.

Hepatic decompensation is the major driver of mortality in patients with HCC treated with atezolizumab plus bevacizumab: The impact of successful antiviral treatment
Celsa C, Cabibbo G, Fulgenzi C, Battaglia S, Enea M, Scheiner B, D'Alessio A, Manfredi G, Stefanini B, Nishida N, Galle P, Schulze K, Wege H, Ciccia R, Hsu W, Vivaldi C, Wietharn B, Lin R, Pirozzi A, Pressiani T, Dalbeni A, Natola L, Auriemma A, Rigamonti C, Burlone M, Parisi A, Huang Y, Lee P, Ang C, Marron T, Pinter M, Cheon J, Phen S, Singal A, Gampa A, Pillai A, Roehlen N, Thimme R, Vogel A, Soror N, Ulahannan S, Sharma R, Sacerdoti D, Pirisi M, Rimassa L, Lin C, Saeed A, Masi G, Schönlein M, von Felden J, Kudo M, Cortellini A, Chon H, Cammà C, Pinato D
HEPATOLOGY. 2024 [Epub ahead of print].

Immunotherapy vs Best Supportive Care for Patients With Hepatocellular Cancer With Child-Pugh B Dysfunction
Fulgenzi C, Scheiner B, D'Alessio A, Mehan A, Manfredi G, Celsa C, Nishida N, Ang C, Marron T, Wu L, Saeed A, Wietharn B, Cammarota A, Pressiani T, Pinter M, Sharma R, Cheon J, Huang Y, Lee P, Phen S, Gampa A, Pillai A, Napolitano A, Vivaldi C, Salani F, Masi G, Silletta M, Lo Prinzi F, Di Giacomo E, Vincenzi B, Bettinger D, Thimme R, Vogel A, Schönlein M, von Felden J, Schulze K, Wege H, Galle P, Pirisi M, Park J, Kudo M, Rimassa L, Singal A, El Tomb P, Ulahannan S, Parisi A, Chon H, Hsu W, Ghittoni G, Cammà C, Stefanini B, Trevisani F, Giannini E, Cortellini A, Pinato D
JAMA ONCOL. 2024;10(9):1253-1258.

Soluble and EV-bound CD27 act as antagonistic biomarkers in patients with solid tumors undergoing immunotherapy
Gorgulho J, Schulze K, Sinn M, Bokemeyer C, von Felden J
J EXP CLIN CANC RES. 2024;43(1):298.

Corrigendum: PD-1/PD-L1 immune checkpoint therapy demonstrates favorable safety profile in patients with autoimmune and cholestatic liver disease
Kocheise L, Piseddu I, Vonderlin J, Tjwa E, Buescher G, Meunier L, Goeggelmann P, Fianchi F, Dumortier J, Barciela M, Gevers T, Beretta-Piccoli B, Londoño M, Frankova S, Roesner T, Joerg V, Schmidt C, Glaser F, Sutter J, Fründt T, Lohse A, Huber S, von Felden J, Sebode M, Schulze K
FRONT IMMUNOL. 2024;15:1369747.

Radiofrequency ablation via catheter and transpapillary access in patients with cholangiocarcinoma (ACTICCA-2 trial) - a multicenter, randomized, controlled, open-label investigator-initiated trial
Schmidt C, Zapf A, Ozga A, Canbay A, Denzer U, De Toni E, Lohse A, Schulze K, Rösch T, Stein A, Wege H, von Felden J
BMC CANCER. 2024;24(1):.

Efficacy and safety of palliative treatment in patients with autoimmune liver disease-associated hepatocellular carcinoma
Stern L, Schmidt C, Kocheise L, Joerg V, Casar C, Walter A, Drenth J, Papp M, Gatselis N, Zachou K, Pinter M, Scheiner B, Vogel A, Kirstein M, Finkelmeier F, Waidmann O, Weinmann A, Milkiewicz P, Thorburn D, Halliday N, Lleo A, Huber S, Dalekos G, Lohse A, Wege H, von Felden J, Schulze K
ANN HEPATOL. 2024;29(6):101534.

Tissue resident iNKT17 cells facilitate cancer cell extravasation in liver metastasis via interleukin-22
Giannou A, Kempski J, Shiri A, Lücke J, Zhang T, Zhao L, Zazara D, Cortesi F, Riecken K, Amezcua Vesely M, Low J, Xu H, Kaffe E, Garcia-Perez L, Agalioti T, Yamada Y, Jungraithmayr W, Zigmond E, Karstens K, Steglich B, Wagner J, Konczalla L, Carambia A, Schulze K, von Felden J, May P, Briukhovetska D, Bedke T, Brockmann L, Starzonek S, Lange T, Koch C, Riethdorf S, Pelczar P, Böttcher M, Sabihi M, Huber F, Reeh M, Grass J, Wahib R, Seese H, Stüben B, Fard-Aghaie M, Duprée A, Scognamiglio P, Plitzko G, Meiners J, Soukou S, Wittek A, Manthey C, Maroulis I, Arck P, Perez D, Gao B, Zarogiannis S, Strowig T, Pasqualini R, Arap W, Gosálvez J, Kobold S, Prinz I, Guse A, Tachezy M, Ghadban T, Heumann A, Li J, Melling N, Mann O, Izbicki J, Pantel K, Schumacher U, Lohse A, Flavell R, Gagliani N, Huber S
IMMUNITY. 2023;56(1):125-142.e12.

Efficacy and safety of atezolizumab/bevacizumab in patients with HCC after prior systemic therapy: A global, observational study
Joerg V, Scheiner B, D Alessio A, Fulgenzi C, Schönlein M, Kocheise L, Lohse A, Huber S, Wege H, Kaseb A, Wang Y, Mathew A, Kuang A, Muzaffar M, Abugabal Y, Chamseddine S, Phen S, Cheon J, Lee P, Balcar L, Krall A, Ang C, Wu L, Saeed A, Huang Y, Bengsch B, Rimassa L, Weinmann A, Stauber R, Korolewicz J, Pinter M, Singal A, Chon H, Pinato D, Schulze K, von Felden J
HEPATOL COMMUN. 2023;7(11):.

PD-1/PD-L1 immune checkpoint therapy demonstrates favorable safety profile in patients with autoimmune and cholestatic liver disease
Kocheise L, Piseddu I, Vonderlin J, Tjwa E, Buescher G, Meunier L, Goeggelmann P, Fianchi F, Dumortier J, Riveiro Barciela M, Gevers T, Terziroli Beretta-Piccoli B, Londoño M, Frankova S, Roesner T, Joerg V, Schmidt C, Glaser F, Sutter J, Fründt T, Lohse A, Huber S, von Felden J, Sebode M, Schulze K
FRONT IMMUNOL. 2023;14:1326078.

EpCAM-positive circulating tumor cells and serum AFP levels predict outcome after curative resection of hepatocellular carcinoma
Kocheise L, Schoenlein M, Behrends B, Joerg V, Casar C, Fründt T, Renné T, Heumann A, Li J, Huber S, Lohse A, Pantel K, Riethdorf S, Wege H, Schulze K, von Felden J
SCI REP-UK. 2023;13(1):20827.

Efficacy and safety of immune checkpoint inhibitor rechallenge in individuals with hepatocellular carcinoma
Scheiner B, Roessler D, Phen S, Lim M, Pomej K, Pressiani T, Cammarota A, Fründt T, von Felden J, Schulze K, Himmelsbach V, Finkelmeier F, Deibel A, Siebenhüner A, Shmanko K, Radu P, Schwacha-Eipper B, Ebert M, Teufel A, Djanani A, Hucke F, Balcar L, Philipp A, Hsiehchen D, Venerito M, Sinner F, Trauner M, D'Alessio A, Fulgenzi C, Pinato D, Peck-Radosavljevic M, Dufour J, Weinmann A, Kremer A, Singal A, De Toni E, Rimassa L, Pinter M
JHEP REP. 2023;5(1):.

Impact of body mass index in patients receiving atezolizumab plus bevacizumab for hepatocellular carcinoma
Vithayathil M, D'Alessio A, Fulgenzi C, Nishida N, Schönlein M, von Felden J, Schulze K, Wege H, Saeed A, Wietharn B, Hildebrand H, Wu L, Ang C, Marron T, Weinmann A, Galle P, Bettinger D, Bengsch B, Vogel A, Balcar L, Scheiner B, Lee P, Huang Y, Amara S, Muzaffar M, Naqash A, Cammarota A, Zanuso V, Pressiani T, Pinter M, Cortellini A, Kudo M, Rimassa L, Pinato D, Sharma R
HEPATOL INT. 2023;17(4):904-914.

Preliminary evidence of safety and tolerability of atezolizumab plus bevacizumab in patients with hepatocellular carcinoma and Child-Pugh A and B cirrhosis: a real-world study
D'Alessio A, Fulgenzi C, Nishida N, Schönlein M, von Felden J, Schulze K, Wege H, Gaillard V, Saeed A, Wietharn B, Hildebrand H, Wu L, Ang C, Marron T, Weinmann A, Galle P, Bettinger D, Bengsch B, Vogel A, Balcar L, Scheiner B, Lee P, Huang Y, Amara S, Muzaffar M, Naqash A, Cammarota A, Personeni N, Pressiani T, Sharma R, Pinter M, Cortellini A, Kudo M, Rimassa L, Pinato D
HEPATOLOGY. 2022;76(4):1000-1012.

Equal Efficacy and Safety Profile in Elderly Patients with Hepatocellular Carcinoma Receiving Palliative Treatment
Fründt T, Casar C, von Felden J, Schöler U, Priebe M, Kraczyk J, Ahrend H, Salamon J, Adam G, Huber S, Lohse A, Wege H, Schulze K
CANCERS. 2022;14(3):.

Circulating tumor cells as a preoperative risk marker for occult metastases in patients with resectable cholangiocarcinoma
Fründt T, von Felden J, Krause J, Heumann A, Li J, Riethdorf S, Pantel K, Huber S, Lohse A, Wege H, Schulze K
FRONT ONCOL. 2022;12:.

Reproducible safety and efficacy of atezolizumab plus bevacizumab for HCC in clinical practice: Results of the AB-real study
Fulgenzi C, Cheon J, D'Alessio A, Nishida N, Ang C, Marron T, Wu L, Saeed A, Wietharn B, Cammarota A, Pressiani T, Personeni N, Pinter M, Scheiner B, Balcar L, Napolitano A, Huang Y, Phen S, Naqash A, Vivaldi C, Salani F, Masi G, Bettinger D, Vogel A, Schönlein M, von Felden J, Schulze K, Wege H, Galle P, Kudo M, Rimassa L, Singal A, Sharma R, Cortellini A, Gaillard V, Chon H, Pinato D
EUR J CANCER. 2022;175:204-213.

A Critical Role of the IL-22-IL-22 Binding Protein Axis in Hepatocellular Carcinoma
Giannou A, Lücke J, Kleinschmidt D, Shiri A, Steglich B, Nawrocki M, Zhang T, Zazara D, Kempski J, Zhao L, Giannou O, Agalioti T, Brockmann L, Bertram F, Sabihi M, Böttcher M, Ewald F, Schulze K, von Felden J, Machicote A, Maroulis I, Arck P, Graß J, Mercanoglu B, Reeh M, Wolter S, Tachezy M, Seese H, Theodorakopoulou M, Lykoudis P, Heumann A, Uzunoglu F, Ghadban T, Mann O, Izbicki J, Li J, Duprée A, Melling N, Gagliani N, Huber S
CANCERS. 2022;14(24):.

Prognosis of patients with hepatocellular carcinoma treated with immunotherapy - development and validation of the CRAFITY score
Scheiner B, Pomej K, Kirstein M, Hucke F, Finkelmeier F, Waidmann O, Himmelsbach V, Schulze K, von Felden J, Fründt T, Stadler M, Heinzl H, Shmanko K, Spahn S, Radu P, Siebenhüner A, Mertens J, Rahbari N, Kütting F, Waldschmidt D, Ebert M, Teufel A, De Dosso S, Pinato D, Pressiani T, Meischl T, Balcar L, Müller C, Mandorfer M, Reiberger T, Trauner M, Personeni N, Rimassa L, Bitzer M, Trojan J, Weinmann A, Wege H, Dufour J, Peck-Radosavljevic M, Vogel A, Pinter M
J HEPATOL. 2022;76(2):353-363.

Impact of older age in patients receiving atezolizumab and bevacizumab for hepatocellular carcinoma
Vithayathil M, D'Alessio A, Fulgenzi C, Nishida N, Schönlein M, von Felden J, Schulze K, Wege H, Saeed A, Wietharn B, Hildebrand H, Wu L, Ang C, Marron T, Weinmann A, Galle P, Bettinger D, Bengsch B, Vogel A, Balcar L, Scheiner B, Lee P, Huang Y, Amara S, Muzaffar M, Naqash A, Cammarota A, Personeni N, Pressiani T, Pinter M, Cortellini A, Kudo M, Rimassa L, Pinato D, Sharma R
LIVER INT. 2022;42(11):2538-2547.

Neutrophil-to-Lymphocyte and Platelet-to-Lymphocyte Ratios as Prognostic Biomarkers in Unresectable Hepatocellular Carcinoma Treated with Atezolizumab plus Bevacizumab
Wu Y, Fulgenzi C, D'Alessio A, Cheon J, Nishida N, Saeed A, Wietharn B, Cammarota A, Pressiani T, Personeni N, Pinter M, Scheiner B, Balcar L, Huang Y, Phen S, Naqash A, Vivaldi C, Salani F, Masi G, Bettinger D, Vogel A, Schönlein M, von Felden J, Schulze K, Wege H, Galle P, Kudo M, Rimassa L, Singal A, Sharma R, Cortellini A, Gaillard V, Chon H, Pinato D, Ang C
CANCERS. 2022;14(23):.

Diagnostic and Prognostic Value of miR-16, miR-146a, miR-192 and miR-221 in Exosomes of Hepatocellular Carcinoma and Liver Cirrhosis Patients
Fründt T, Krause L, Hussey E, Steinbach B, Köhler D, von Felden J, Schulze K, Lohse A, Wege H, Schwarzenbach H
CANCERS. 2021;13(10):2484.

NASH limits anti-tumour surveillance in immunotherapy-treated HCC
Pfister D, Núñez N, Pinyol R, Govaere O, Pinter M, Szydlowska M, Gupta R, Qiu M, Deczkowska A, Weiner A, Müller F, Sinha A, Friebel E, Engleitner T, Lenggenhager D, Moncsek A, Heide D, Stirm K, Kosla J, Kotsiliti E, Leone V, Dudek M, Yousuf S, Inverso D, Singh I, Teijeiro A, Castet F, Montironi C, Haber P, Tiniakos D, Bedossa P, Cockell S, Younes R, Vacca M, Marra F, Schattenberg J, Allison M, Bugianesi E, Ratziu V, Pressiani T, D'Alessio A, Personeni N, Rimassa L, Daly A, Scheiner B, Pomej K, Kirstein M, Vogel A, Peck-Radosavljevic M, Hucke F, Finkelmeier F, Waidmann O, Trojan J, Schulze K, Wege H, Koch S, Weinmann A, Bueter M, Rössler F, Siebenhüner A, De Dosso S, Mallm J, Umansky V, Jugold M, Luedde T, Schietinger A, Schirmacher P, Emu B, Augustin H, Billeter A, Müller-Stich B, Kikuchi H, Duda D, Kütting F, Waldschmidt D, Ebert M, Rahbari N, Mei H, Schulz A, Ringelhan M, Malek N, Spahn S, Bitzer M, Ruiz de Galarreta M, Lujambio A, Dufour J, Marron T, Kaseb A, Kudo M, Huang Y, Djouder N, Wolter K, Zender L, Marche P, Decaens T, Pinato D, Rad R, Mertens J, Weber A, Unger K, Meissner F, Roth S, Jilkova Z, Claassen M, Anstee Q, Amit I, Knolle P, Becher B, Llovet J, Heikenwalder M
NATURE. 2021;592(7854):450-456.

Early Detection of Hepatocellular Carcinoma Since the Introduction of the German Clinical Practice Guideline in 2013
Schulze K, Felden J, Fründt T, Krause J, Werner T, Casar C, Jung C, Ittrich H, Sterneck M, Li J, Heumann A, Fischer L, Adam G, Lohse A, Wege H
DTSCH ARZTEBL INT. 2021;118(31-32):540-541.

Sequential Systemic Treatment in Advanced Hepatocellular Carcinoma Is Able to Prolong Median Survival to More than 3 Years in a Selected Real-World Cohort
von Felden J, Karkmann K, Ittrich H, Gil-Ibanez I, Fründt T, Krause J, Lohse A, Wege H, Schulze K
VISC MED. 2021;37(2):87-93.

Rare variants of primary liver cancer: Fibrolamellar, combined, and sarcomatoid hepatocellular carcinomas
Wege H, Schulze K, von Felden J, Calderaro J, Reig M
EUR J MED GENET. 2021;64(11):.

GALAD Score Detects Early Hepatocellular Carcinoma in an International Cohort of Patients With Nonalcoholic Steatohepatitis
Best J, Bechmann L, Sowa J, Sydor S, Dechêne A, Pflanz K, Bedreli S, Schotten C, Geier A, Berg T, Fischer J, Vogel A, Bantel H, Weinmann A, Schattenberg J, Huber Y, Wege H, von Felden J, Schulze K, Bettinger D, Thimme R, Sinner F, Schütte K, Weiss K, Toyoda H, Yasuda S, Kumada T, Berhane S, Wichert M, Heider D, Gerken G, Johnson P, Canbay A
CLIN GASTROENTEROL H. 2020;18(3):728-735.e4.

Hepatocellular carcinoma: Intratumoral EpCAM-positive cancer stem cell heterogeneity identifies high-risk tumor subtype
Krause J, von Felden J, Casar C, Fründt T, Galaski J, Schmidt C, Jung C, Ittrich H, Weidemann S, Krech T, Heumann A, Li J, Fischer L, Sauter G, Lohse A, Wege H, Schulze K
BMC CANCER. 2020;20(1):1130.

Liquid biopsy in the clinical management of hepatocellular carcinoma
von Felden J, Garcia-Lezana T, Schulze K, Losic B, Villanueva A
GUT. 2020;69(11):2025-2034.

Elevated Aspartate Aminotransferase to Alanine Aminotransferase Ratio Predicts Poor Outcome in Hepatocellular Carcinoma
von Felden J, Wege H, Schulze K
HEPATOL COMMUN. 2020;4(9):1382-1383.

Programmed cell death protein-1 (PD-1)-targeted immunotherapy in advanced hepatocellular carcinoma: efficacy and safety data from an international multicentre real-world cohort
Scheiner B, Kirstein M, Hucke F, Finkelmeier F, Schulze K, von Felden J, Koch S, Schwabl P, Hinrichs J, Waneck F, Waidmann O, Reiberger T, Müller C, Sieghart W, Trauner M, Weinmann A, Wege H, Trojan J, Peck-Radosavljevic M, Vogel A, Pinter M
ALIMENT PHARM THER. 2019;49(10):1323-1333.

Neue Optionen in der Systemtherapie des hepatozellulären Karzinoms
Wege H, Schulze K
TUMORDIAGN THER. 2018;9(39):590-594.

High expression of micro RNA-135A in hepatocellular carcinoma is associated with recurrence within 12 months after resection
von Felden J, Heim D, Schulze K, Krech T, Ewald F, Nashan B, Lohse A, Wege H
BMC CANCER. 2017;17(1):60.

Circulating tumor cells as liquid biomarker for high HCC recurrence risk after curative liver resection
von Felden J, Schulze K, Krech T, Ewald F, Nashan B, Pantel K, Lohse A, Riethdorf S, Wege H
ONCOTARGET. 2017;8(52):89978-89987.

Patient Age, Sex, and Inflammatory Bowel Disease Phenotype Associate With Course of Primary Sclerosing Cholangitis
Weismüller T, Trivedi P, Bergquist A, Imam M, Lenzen H, Ponsioen C, Holm K, Gotthardt D, Färkkilä M, Marschall H, Thorburn D, Weersma R, Fevery J, Mueller T, Chazouillères O, Schulze K, Lazaridis K, Almer S, Pereira S, Levy C, Mason A, Naess S, Bowlus C, Floreani A, Halilbasic E, Yimam K, Milkiewicz P, Beuers U, Huynh D, Pares A, Manser C, Dalekos G, Eksteen B, Invernizzi P, Berg C, Kirchner G, Sarrazin C, Zimmer V, Fabris L, Braun F, Marzioni M, Juran B, Said K, Rupp C, Jokelainen K, Benito de Valle M, Saffioti F, Cheung A, Trauner M, Schramm C, Chapman R, Karlsen T, Schrumpf E, Strassburg C, Manns M, Lindor K, Hirschfield G, Hansen B, Boberg K
GASTROENTEROLOGY. 2017;152(8):1975-1984.e8.

Validation of Transient Elastography and Comparison with Spleen Length Measurement for Staging of Fibrosis and Clinical Prognosis in Primary Sclerosing Cholangitis
Ehlken H, Wroblewski R, Corpechot C, Arrivé L, Rieger T, Hartl J, Lezius S, Hübener P, Schulze K, Zenouzi R, Sebode M, Peiseler M, Denzer U, Quaas A, Weiler-Normann C, Lohse A, Chazouilleres O, Schramm C
PLOS ONE. 2016;11(10):e0164224.

CT-P13 (Inflectra™, Remsima™) monitoring in patients with inflammatory bowel disease
Schulze K, Koppka N, Lutter F, Brandhorst G, Helwig U
BIOLOGICALS. 2016;44(5):463-6.

Genetic profiling of hepatocellular carcinoma using next-generation sequencing
Schulze K, Nault J, Villanueva A
J HEPATOL. 2016;65(5):1031-1042.

Translating the molecular diversity of hepatocellular carcinoma into clinical practice
Schulze K, Zucman-Rossi J
MOL CELL ONCOL. 2016;3(4):e1057316.

First- and Second-Line Targeted Systemic Therapy in Hepatocellular Carcinoma-An Update on Patient Selection and Response Evaluation
von Felden J, Schulze K, Gil-Ibanez I, Werner T, Wege H
DIAGNOSTICS. 2016;6(4):E44.

No Evidence That Azathioprine Increases Risk of Cholangiocarcinoma in Patients With Primary Sclerosing Cholangitis
Zenouzi R, Weismüller T, Jørgensen K, Bubenheim M, Lenzen H, Hübener P, Schulze K, Weiler-Normann C, Sebode M, Ehlken H, Pannicke N, Hartl J, Peiseler M, Hübener S, Karlsen T, Boberg K, Manns M, Lohse A, Schramm C
CLIN GASTROENTEROL H. 2016;14(12):1806-1812.

Retroviral insertional mutagenesis in telomerase-immortalized hepatocytes identifies RIPK4 as novel tumor suppressor in human hepatocarcinogenesis
Heim D, Cornils K, Schulze K, Fehse B, Lohse A, Brümmendorf T, Wege H
ONCOGENE. 2015;34(3):385-393.

Exome sequencing of hepatocellular carcinomas identifies new mutational signatures and potential therapeutic targets
Schulze K, Imbeaud S, Letouzé E, Alexandrov L, Calderaro J, Rebouissou S, Couchy G, Meiller C, Shinde J, Soysouvanh F, Calatayud A, Pinyol R, Pelletier L, Balabaud C, Laurent A, Blanc J, Mazzaferro V, Calvo F, Villanueva A, Nault J, Bioulac-Sage P, Stratton M, Llovet J, Zucman-Rossi J
NAT GENET. 2015;47(5):505-11.

Criteria Used in Clinical Practice to Guide Immunosuppressive Treatment in Patients with PrimarCortico-Cerebellar Structural Connectivity Is Related to Residual Motor Output in Chronic Strokey Sclerosing Cholangitis
Schulze K, Weismüller T, Bubenheim M, Hübener P, Zenouzi R, Lenzen H, Rupp C, Gotthardt D, de Leuw P, Teufel A, Zimmer V, Reiter F, Rust C, Tharun L, Quaas A, Weidemann S, Lammert F, Sarrazin C, Manns M, Lohse A, Schramm C
PLOS ONE. 2015;10(10):Art. e0140525.

Determination of ethyl glucuronide in hair for detection of alcohol consumption in patients after liver transplantation
Sterneck M, von Rothkirch G, Andresen-Streichert H, Vettorazzi E, Schulze K, Nashan B
2014. AMERICAN JOURNAL OF TRANSPLANTATION. .

Low Risk of Hepatocellular Carcinoma in Patients With Primary Sclerosing Cholangitis With Cirrhosis
Zenouzi R, Weismüller T, Hübener P, Schulze K, Bubenheim M, Pannicke N, Weiler-Normann C, Lenzen H, Manns M, Lohse A, Schramm C
CLIN GASTROENTEROL H. 2014.

Presence of EpCAM-positive circulating tumor cells as biomarker for systemic disease strongly correlates to survival in patients with hepatocellular carcinoma
Schulze K, Gasch C, Staufer K, Nashan B, Lohse A, Pantel K, Riethdorf S, Wege H
INT J CANCER. 2013;133(9):2165-71.

[Immune reconstitution inflammatory syndrome in cryptococcal meningitis: a rare phenomenon?].
Schulze K, Schmiedel S, van Lunzen J
DEUT MED WOCHENSCHR. 2012;137(16):834-837.

Lebererkrankungen in der Schwangerschaft
Schulze K, Lüth S
GASTROENTEROLOGE. 2011;6(4):337-346.

Letzte Aktualisierung aus dem FIS: 21.12.2024 - 03:58 Uhr